Vyne Therapeutics
Late stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $88.2m | Private Placement VC |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (30 %) | (97 %) | (11 %) | 18 % | 40 % | (36 %) | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (462 %) | (7114 %) | (6900 %) | (8709 %) | (4471 %) | (11267 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (497 %) | (4866 %) | (6710 %) | (7951 %) | (5623 %) | (9907 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 169 % | 3854 % | 3846 % | 6177 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
VYNE Therapeutics is an entrepreneurial biopharmaceutical company focused on developing innovative and differentiated therapies to address some of the most difficult therapeutic challenges. The company leverages its existing development capabilities and a strong network of discovery and preclinical science partners to advance new medicines through the clinical pipeline. VYNE Therapeutics operates in the biopharmaceutical market, primarily serving patients with unmet medical needs. The business model revolves around the development and commercialization of proprietary therapies, generating revenue through product sales and potential partnerships or licensing agreements. The company's approach is rooted in questioning traditional assumptions and finding better solutions, driven by a culture of collaborative teamwork and independent thinking.
Keywords: biopharmaceutical, innovative therapies, proprietary, differentiated, clinical pipeline, unmet medical needs, product sales, partnerships, licensing, entrepreneurial.